Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
about
Multimodal management of muscle-invasive bladder cancerA phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urotheliumRandomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma.Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report.The prognostic value of histological subtype in patients with metastatic bladder cancerFirst- and second-line therapy for metastatic urothelial carcinoma of the bladderPaclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract.Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patients.Denosumab: a new option in the treatment of bone metastases from urological cancersSystemic chemotherapy options for metastatic bladder cancer.A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo.Chemotherapy practices and perspectives in invasive bladder cancer.Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.Systemic therapy for metastatic urothelial carcinoma.Current optimal chemotherapy for advanced urothelial cancer.Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patientsSEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016).Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma.Oncological outcomes of advanced muscle-invasive bladder cancer with a micropapillary variant after radical cystectomy and adjuvant platinum-based chemotherapy.Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?Targeting the VEGF pathway in metastatic bladder cancer.Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial CarcinomaValidation of major prognostic models for metastatic urothelial carcinoma using a multi-institutional cohort of the real world.Long-term survival in bone-predominant metastatic urothelial carcinoma.Patient characteristics and outcomes in metastatic upper tract urothelial carcinoma after radical nephroureterectomy: the experience of Japanese multi-institutions.The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy.Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host.Successful treatment of chemo-refractory pulmonary metastases of renal pelvic cancer by second-line chemotherapy including gemcitabine followed by salvage surgery.Could salvage surgery after chemotherapy have clinical impact on cancer survival of patients with metastatic urothelial carcinoma?
P2860
Q27011624-5D9E858E-89C4-47BD-B208-37B6BFE8CAA6Q33287243-30530D00-3A8D-453E-874D-19F64D69B03EQ33399928-9275036A-B596-43D3-BBB9-7295E1049730Q33621281-5988F079-C985-40B8-9ECD-8F67976174B8Q33638615-BF933562-7EC4-4438-BDC5-310A62B357DEQ33709712-5D079435-9862-4275-A641-1CD5F44D5C2AQ34541463-C0461F34-52AA-4737-B500-AD8B993050C2Q35649367-466864BB-1588-4ADF-83C7-DE1A6372327DQ36270475-6F5F988E-D1A3-4B6D-A2A7-7CAC04854B25Q36277837-1F6C7CC7-1927-4F89-9BDB-3E5CCAFBC564Q36500537-3E03A39C-9697-47B2-A2CC-AC08858C10BAQ36612034-B483E40D-4A52-40A4-8EC4-677268BAEAA5Q36636656-35894C25-AB62-43B7-89E3-3E6C86F89F15Q36953563-52221080-87D1-446E-831E-47A071980858Q37003299-C5493755-BF4B-4C46-A0A7-157E4ED6BD6AQ37028356-8817A6A8-F358-4B62-82CB-059F004B7DE6Q37038897-65450023-3EE1-4A97-A017-3B2A4C6C28C4Q37158538-2D79E247-BA09-4D0E-A41E-3A0DCA3004B2Q37475193-34288FE5-D07D-4632-BB13-05BE07D3569CQ37896172-1BA5AB0B-2551-4B6C-B6B4-C199B47A573EQ38245360-A5948C93-144F-4A64-AFE7-F3E1DD1FC602Q38312045-E56ADD93-C68B-41AE-8C4C-A32C80283160Q38534167-6C1FDCCC-42DA-4954-8D07-1B84125938F3Q41002840-A7B28BB5-8B82-48A1-B4DC-D53483F94AF4Q41620841-B9217F64-50B2-4F75-8766-B94177000BCAQ43051044-2BF5DA8D-5848-4666-BABA-0B052A6319BDQ43424908-6CCB2ABD-DD67-46FA-AA68-A128C385E43BQ43489127-878FDA65-18D3-4B6C-A175-B59E45F6BF8DQ43542810-93DB80E9-7F00-4B85-9FA7-81ADEACFB9ACQ43879300-174D12B8-1E06-424E-BC41-9F03FB2EA048Q45283898-06A0EF8A-DD26-41F9-9193-79325630437FQ45342949-9184086C-8168-4560-A9F5-8ECA92D4FAF7
P2860
Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Pretreatment prognostic factor ...... l, cisplatin, and gemcitabine.
@en
Pretreatment prognostic factor ...... l, cisplatin, and gemcitabine.
@nl
type
label
Pretreatment prognostic factor ...... l, cisplatin, and gemcitabine.
@en
Pretreatment prognostic factor ...... l, cisplatin, and gemcitabine.
@nl
prefLabel
Pretreatment prognostic factor ...... l, cisplatin, and gemcitabine.
@en
Pretreatment prognostic factor ...... l, cisplatin, and gemcitabine.
@nl
P2093
P2860
P50
P356
P1433
P1476
Pretreatment prognostic factor ...... el, cisplatin, and gemcitabine
@en
P2093
Hernan Cortés-Funes
Joan Albanell
Joaquim Bellmunt
José Baselga
Juan J de la Cruz
Luis Paz-Ares
Miguel A Climent
Spanish Oncology Genitourinary Group
Vicente Guillem
P2860
P304
P356
10.1002/CNCR.10762
P407
P577
2002-08-01T00:00:00Z